Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

20 Jul 2011

Abstract excerpt

Interactions between histone deacetylase inhibitors (HDACIs) and decitabine were investigated in models of diffuse large B-cell lymphoma (DLBCL). A number of cell lines representing both germinal center B-like and activated B-cell like DLBCL, patient-derived tumor cells and a murine xenograft model were used to study the effects of HDACIs and decitabine in this system. All explored HDACIs in combination with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21772049
DOI: 10.1182/blood-2011-02-336891

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCLPMID 21772049Read ↗

Targeting HDACs for diffuse large B-cell lymphoma therapySemantic proximity Read ↗

Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphomaSemantic proximity Read ↗

Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypesSemantic proximity Read ↗

Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclaxSemantic proximity Read ↗

DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell LymphomasSemantic proximity Read ↗

The Sensitivity of Diffuse Large B-Cell Lymphoma Cell Lines to Histone Deacetylase Inhibitor-Induced Apoptosis Is Modulated by BCL-2 Family Protein ActivitySemantic proximity Read ↗

miR-28 plus ibrutinib as a novel combination therapy for Diffuse Large B Cell LymphomaSemantic proximity Read ↗

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.Semantic proximity Read ↗

Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell LymphomaSemantic proximity Read ↗

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cellsSemantic proximity Read ↗

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non–Small Cell Lung CancerSemantic proximity Read ↗

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer AgentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.